Home > Focus Areas > COPD Connect > Post
  • Saved

2mo
case study

Patient Background:

Mr. H is a 66-year-old male retired factory worker with a 45-pack-year smoking history who currently smokes 5 cigarettes daily. He has a 5-year history of chronic obstructive pulmonary disease (COPD) and reports worsening exertional dyspnea (mMRC grade 2), chronic productive morning cough, and one moderate COPD exacerbation during the past year requiring oral corticosteroids.

He has been receiving inhaled long-acting muscarinic antagonist (LAMA) monotherapy for 2 years with partial symptom control. Comorbidities include hypertension and benign prostatic hypertrophy managed with tamsulosin. He has no history of asthma or eosinophilia.

Assessment & Diagnosis:

Spirometry demonstrates an FEV1/FVC ratio of 0.58 and FEV1 of 56% predicted, consistent with GOLD Stage 2, Group B COPD. COPD Assessment Test (CAT) score is 18, indicating…read more

high symptom burden. Six-minute walk test distance is 310 meters. CT imaging demonstrates emphysema-predominant disease.

Given persistent dyspnea despite LAMA monotherapy and absence of eosinophilia or asthma features, the care team escalates to once-daily dual bronchodilator therapy using a fixed-dose LAMA/LABA combination administered via a soft mist inhaler. Smoking cessation counseling was reinforced.

  1. Please provide a minimum of a 3 sentence response.
  2. 1.Which COPD phenotype features support escalation from LAMA monotherapy to fixed-dose LAMA/LABA therapy?
  3. 2.What inhaler technique and adherence barriers should be assessed when initiating soft mist inhaler therapy?
  4. 3.How should symptom burden and functional response be monitored after escalation to dual bronchodilator therapy?

Show Less

  • 2mo
    This patient with Chronic Obstructive Pulmonary Disease shows clear features supporting escalation from LAMA monotherapy to fixed-dose LAMA/LABA therapy, including persistent dyspnea (mMRC ≥2), elevated symptom burden (CAT 18), and at least one recent moderate exacerbation despite treatment. Additional phenotype factors supporting escalation include ongoing airflow limitation (FEV1 56% predicted), chronic bronchitis symptoms, and continued smoking, all of which increase risk of poor symptom control and future exacerbations. In such patients, dual bronchodilation is typically preferred to improve lung function, reduce symptoms, and potentially lower exacerbation risk.

    When initiating a soft mist inhaler, key barriers to assess include incorrect device preparation, inadequate inspiratory flow coordination, poor hand–breath coordination, and misunderstanding of dosing frequency or maintenance versus rescue use. It is also important to evaluate physical limitations such as arthritis or cognitive impairment that may affect device handling, as well as adherence issues related to smoking behavior or lack of perceived benefit. Direct inhaler technique demonstration and teach-back are essential to ensure correct use.

    After escalation to dual bronchodilator therapy, symptom burden and functional response should be monitored using tools such as CAT score, mMRC dyspnea scale, and exercise tolerance (e.g., walking distance or daily activity levels). Follow-up should also assess exacerbation frequency, rescue inhaler use, and patient-reported quality of life over several weeks to months. Lack of improvement may prompt reassessment of inhaler technique, adherence, or consideration of alternative/add-on therapies.
  • 2mo
    1: patients without a steroid responding component who are symptomatic.
    2: usually have the nurse do training initially and at follow up visits
    3: exacerbations and continuing symptoms should prompt increased therapy